CDSCO panel eases approval steps for generic lenacapavir
Indian drugmakers are moving closer to launching affordable generic lenacapavir after a CDSCO regulatory panel recommended waiving local late-stage clinical trials.
Indian drugmakers are moving closer to launching affordable generic versions of Gilead Sciences’ long-acting HIV drug lenacapavir after a key regulatory panel recommended waiving local late-stage clinical trials, removing an important hurdle to bringing the landmark therapy to India.Emcure Pharmace…